Changing Treatment Paradigms for Multiple Myeloma
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: closed (15 September 2023) | Viewed by 232
Special Issue Editor
Special Issue Information
Dear Colleagues,
Multiple myeloma refers to a genetically heterogeneous disease of terminally differentiated plasma cells that arises in the bone marrow. The microenvironment plays a fundamental role in multiple myeloma as it provides soluble and membrane-bound factors that sustain malignant cells by promoting cell proliferation and resistance to therapy. This reliance of myeloma cells on the bone marrow microenvironment makes them extremely efficient in disseminating into this protective niche. Indeed, the majority of malignant plasma cells are found in the bone marrow, with only few cells seen in the circulation and, at later stages, in extramedullary sites.
In recent decades, significant improvements in patient progression-free and overall survival have arisen due to the advent of novel therapeutic agents, such as new proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies and chimeric antigen receptor T cells. Importantly, not only do some of these new agents exert direct anti-tumor activity, but also impact upon the tumor microenvironment, inhibiting its pro-tumorigenic potential. Indeed, the anti-CD38 monoclonal antibody Daratumumab displays immunomodulatory functions, such as decreasing the number of regulatory B and T cells, as well as activating CD8-positive T cells.
In this Special Issue of “Current Oncology”, we focus on how these new therapeutic strategies have changed and expanded the treatment options for multiple myeloma. Due to the tremendous increase in the number of novel agents for the treatment of multiple myeloma with diverse mechanisms of action, we would like to invite scientists and clinicians to share and submit their recent studies in this clinically relevant area of investigation.
Dr. Alessandro Natoni
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- tumor microenvironment
- immunomodulatory drugs
- monoclonal antibodies
- bone marrow
- therapy
- immunotherapy
- chemotherapy
- CAR T cells
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
